Company intelligence / Profile preview
Yantai Lannacheng Biotechnology Co., Ltd.
Yantai, Shandong, Chinaen.dc-lnc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LNC has a robust pipeline of proprietary long-acting radiopharmaceuticals based on albumin binders for improved tumor retention and absorbed dose. Several products have received IND approvals from the US FDA, Singapore HSA and China NMPA; lead programs are in advanced clinical stages targeting solid tumors with global reach[1][10].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculespeptidesantibodiesradioligands
- Industry
- Biotech
02
Drug pipeline
24 assets23 more assets in the full pipeline.
03
Partnerships
Parent company DC Pharma provides ecosystem support in nuclear medicine
Beyond the preview
Go deeper on Yantai Lannacheng Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yantai Lannacheng Biotechnology Co., Ltd..